Department of Biomedical Technology, Faculty of Biomedical Engineering, Czech Technical University in Prague, 272 01, Kladno, Czech Republic.
Department of Anesthesiology and Intensive Care, General Teaching Hospital, Prague, Czech Republic.
J Med Syst. 2023 Feb 11;47(1):21. doi: 10.1007/s10916-023-01920-9.
European Union intends to enable cross-border health services through a program referred to as "MyHealth@EU". The first main service is the dispensation of medicine by interlinking national electronic prescription systems. The second one is the Patient Summary, which enables providing the basic set of patients' medical data.
The contemporary technical documentation of the project was studied and selected published Key Performance Indicators of the project were analyzed. Where necessary, data were acquired directly from the European Commission.
Data from the start of the project (fourth quarter of 2019) until the second quarter of 2022 were analyzed. During this time both the overall number of EU countries with operational cross-border healthcare and their particular abilities in both services have risen. At present, there are eleven countries with capabilities in at least one of the services, of which nine have reported transactions. More countries are in the test phase now and will join the operational phase of the project shortly.
Nevertheless, the program is still used mostly for testing purposes. It seems that only electronic prescription and dispensation are commonly and widely used so far and only Estonian and Finnish patients usually get their medication dispensed abroad. The rest of the operational countries is still at present missing country pairs with a strong cross-border use case.
欧盟计划通过一个名为“MyHealth@EU”的项目实现跨境医疗服务。第一个主要服务是通过链接国家电子处方系统来配药。第二个是患者摘要,它可以提供患者基本的医疗数据。
研究并选择了项目的当代技术文档,并分析了项目的选定发布的关键绩效指标。必要时,直接从欧盟委员会获取数据。
分析了从项目开始(2019 年第四季度)到 2022 年第二季度的数据。在此期间,提供跨境医疗服务的欧盟国家数量及其在这两项服务中的具体能力都有所增加。目前,有十一个国家至少在一项服务中具有能力,其中九个国家已经报告了交易。更多的国家目前处于测试阶段,很快将加入该项目的运营阶段。
然而,该计划目前仍主要用于测试目的。到目前为止,似乎只有电子处方和配药被普遍广泛使用,只有爱沙尼亚和芬兰的患者通常在国外获得药物配给。其他运营国家目前仍缺乏具有强大跨境使用案例的国家对。